Compare James Hardie Industries plc. Ordinary Shares (JHX) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
James Hardie Industries plc. Ordinary Shares vs Kymera Therapeutics Inc. Common Stock — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $24.56 (market cap $14.32B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: James Hardie Industries plc. Ordinary Shares is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, James Hardie Industries plc. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 6 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| JHX | KYMR | |
|---|---|---|
Market Cap | $14.32B | $8.87B |
Volume | 5,683,820 | 779,107 |
Sector | Basic Materials | Health |
52-Week High | $31.08 | $127.31 |
52-Week Low | $16.69 | $55.80 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $18.55B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
James Hardie Industries (JHX) trades at $24.67, down 0.36% with a bearish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 112.14 but strong revenue growth from $3.88B to $5.4B projected. Recent earnings beat expectations in Q2 2026, and the company completed strategic divestitures including the $980M Fermacell sale to Holcim. Analyst sentiment remains positive with 70.59% buy ratings and a $34 consensus price target representing 38% upside potential.
JHX presents a growth story with expanding revenues but faces profitability compression as net margins decline from 10.93% to 2.69%. The stock's high valuation multiples require strong execution to justify. Key risks include integration challenges from recent acquisitions, rising debt levels, and housing market sensitivity. Institutional ownership shows mixed signals with State Street reducing its position while short interest increased 47.8% in September 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About James Hardie Industries plc. Ordinary Shares
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
